Anti-Fibrinolytic Drugs - Thailand

Thailand

In Thailand, the Anti-Fibrinolytic Drugs market is expected to witness significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$29.55m.
This indicates a positive trend for the market in the country.
Looking ahead, it is anticipated that the market will continue to grow at an annual growth rate of 4.92% (CAGR 2024-2029), resulting in a market volume of US$37.57m by 2029.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in the Anti-Fibrinolytic Drugs market, with an estimated revenue of US$9,858.00m in 2024.
This demonstrates the dominance of the US market in this particular market.
Thailand's healthcare industry is witnessing a growing demand for anti-fibrinolytic drugs to address the country's rising prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Fibrinolytic Drugs in Thailand has been steadily increasing in recent years.

Customer preferences: Thai customers have been increasingly aware of the importance of these drugs in treating bleeding disorders such as hemophilia and menorrhagia. Additionally, the aging population in Thailand has also contributed to the growth in demand for these drugs as they are more prone to bleeding disorders.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Thailand is the increasing preference for generic drugs over branded drugs. This is mainly due to the lower cost of generic drugs and the government's policy of promoting the use of generic drugs to reduce healthcare costs. Another trend is the increasing use of online pharmacies to purchase these drugs, which has made it more convenient for customers to access them.

Local special circumstances: Thailand has a well-developed healthcare system, with both public and private hospitals and clinics. The government has been actively promoting the use of generic drugs to reduce healthcare costs, which has led to an increase in the availability of generic Anti-Fibrinolytic Drugs in the market. Additionally, the country has a large population of expatriates, who also contribute to the demand for these drugs.

Underlying macroeconomic factors: Thailand has a growing economy, with a GDP growth rate of around 3% in recent years. The country has a large population of around 69 million people, with a rapidly aging population. This has led to an increase in demand for healthcare services, including Anti-Fibrinolytic Drugs. Additionally, the government's policy of promoting the use of generic drugs has helped to reduce healthcare costs and increase the affordability of these drugs for customers.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.